Bio Sequence

Quickly Locating Your Target Sequence in Patent Claims Containing a Large Number of Antibody Sequences

22 September 2023
2 min read

In the vast sea of patents, pinpointing a target sequence can be daunting. Utilizing the Patsnap patent database, alongside its Bio Database, simplifies this process, rendering rapid and accurate results. Here's a step-by-step guide on how to leverage this powerful toolset:

Commence your journey by registering for a free Bio Database account, which can easily be achieved by clicking Patsnap Bio Sequence Database. Once registered, input your patent number, e.g., WO2018020476A1, into Patsnap's patent data search bar. Once located, open the patent to view its detailed page, where its disclosed rights can be viewed on the right-claim page. Then, click Sequence Assistant in the top right corner, enter the target sequence you want to find, such as SASYRYS, and click "Search Sequence," as shown in the figure below.

Toggle the "Sequence Highlight" feature on the right for an even more precise view. Fully matched sequences will be illuminated in red and partially matched in yellow, while the remaining patent sequences will appear in blue. This results in your target sequence, in this case, "SEQ ID NO: 5", being evident and easily located within the claim of rights, displaying all its positions.

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

BeiGene reports positive regulatory developments in Europe and the U.S., following the recent reacquisition of worldwide rights to TEVIMBRA®
Latest Hotspot
4 min read
BeiGene reports positive regulatory developments in Europe and the U.S., following the recent reacquisition of worldwide rights to TEVIMBRA®
22 September 2023
BeiGene, Ltd. revealed that TEVIMBRA®(tislelizumab) has received approval by the EC to be used as a single therapy for addressing unresectable.
Read →
Analysis on the Research Progress of HIV-1 Protease Inhibitors
Analysis on the Research Progress of HIV-1 Protease Inhibitors
22 September 2023
HIV-1 protease is an enzyme that plays a crucial role in the replication of the human immunodeficiency virus (HIV-1) within the human body.
Read →
ESSA Pharma starts Phase 2 trial of EPI-7386 with Enzalutamide for Metastatic Castration-Resistant Prostate Cancer patients
Latest Hotspot
4 min read
ESSA Pharma starts Phase 2 trial of EPI-7386 with Enzalutamide for Metastatic Castration-Resistant Prostate Cancer patients
22 September 2023
ESSA Pharma Begins Phase 2 trial of Masofaniten (EPI-7386) in Combination with Enzalutamide for Patients Suffering from Metastatic Castration-Resistant Prostate Cancer.
Read →
Analysis on the Research Progress of GnRHR antagonists
Analysis on the Research Progress of GnRHR antagonists
22 September 2023
GnRH, also known as Gonadotropin-Releasing Hormone, is a decapeptide hormone secreted by the arcuate nucleus neurons in the hypothalamus.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.